Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are not supported by the provided FDA label excerpts for aspirin/dipyridamole capsules and include multiple quantitative estimates, drug-specific pharmacokinetics, and symptom triage instructions not present in the label. Several statements also do not map to the label’s described warnings/interactions and are therefore unsupported or potentially misleading relative to the supplied labeling.
Category Scores
Accurate Statements
Aspirin and extended-release dipyridamole capsules increase the risk of bleeding, particularly when combined with other drugs that increase bleeding risk (e.g., anticoagulants/antiplatelet agents).
Warnings and Precautions (5.1): “Aspirin and extended-release dipyridamole increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents...)”
Aspirin/dipyridamole has an antithrombotic effect attributable to additive antiplatelet effects of dipyridamole and aspirin.
Clinical Pharmacology (12.1): “...result of the additive antiplatelet effects of dipyridamole and aspirin.”
Unsupported Statements
Adding aspirin to blood thinners increases the risk of major bleeding.
Label states increased bleeding risk with concomitant anticoagulants/antiplatelet agents but provided excerpts do not specifically quantify or describe “major bleeding.”
Major bleeding risk increases from 1–2% per year with blood thinners alone to 3–5% per year when aspirin is combined.
No such numeric risk estimates appear in the provided label excerpts.
Combining aspirin with blood thinners increases gastrointestinal bleeding.
Label excerpt includes GI side effects and gross GI bleeding warning, and increased bleeding risk with anticoagulants/antiplatelets generally, but it does not specifically state the combination increases GI bleeding.
Combining aspirin with blood thinners increases intracranial hemorrhage.
Label excerpt includes intracranial hemorrhage event rate in ESPS2 for aspirin/dipyridamole, and general bleeding risk with anticoagulants/antiplatelets, but does not specifically state the combination increases intracranial hemorrhage.
Gastrointestinal ulcers and diverticular bleeds become more frequent when aspirin is added to blood thinners.
Label warns of peptic ulcer disease and alerts for ulceration/bleeding, but provided excerpts do not mention diverticular bleeds or “become more frequent” when combined with blood thinners.
Intracranial hemorrhage has high mortality once it occurs.
No mortality statement for intracranial hemorrhage is present in provided excerpts.
Aspirin permanently blocks COX-1 in platelets.
No COX-1 mechanism description is present in the provided label excerpts.
Aspirin prevents thromboxane A2 formation.
No thromboxane A2 statement is present in the provided label excerpts.
Aspirin reduces platelet aggregation.
The label supports antiplatelet effects as part of additive antiplatelet action, but this statement is not explicitly provided in the excerpts as a standalone claim for aspirin alone.
Blood thinners inhibit clotting factors or factor Xa.
Provided label excerpts discuss aspirin/dipyridamole and do not describe mechanisms of other “blood thinners.”
When aspirin and blood thinners impair primary and secondary hemostasis simultaneously, bleeding likelihood increases.
Hemostasis mechanism phrasing (primary/secondary) is not present in the provided label excerpts.
Aspirin’s antiplatelet effect lasts 7–10 days after stopping aspirin.
No duration of antiplatelet effect after stopping aspirin is provided in the excerpts.
The antiplatelet effect of aspirin lasts 7–10 days because new platelets must be produced to replace blocked ones.
Neither the 7–10 day duration nor the platelet-production rationale appears in the provided excerpts.
Rivaroxaban clears from the body in 24–48 hours.
No pharmacokinetics for rivaroxaban appear in the provided aspirin/dipyridamole label excerpts.
Apixaban clears from the body in 24–48 hours.
No pharmacokinetics for apixaban appear in the provided aspirin/dipyridamole label excerpts.
The combined risk window remains eroding only when new platelets arrive.
No “risk window” concept or linkage to platelet arrival timing is described in the provided excerpts.
Low-dose aspirin (81 mg) still carries measurable bleeding risk when paired with oral anticoagulants.
Label excerpt indicates bleeding risk increases with anticoagulants, but it does not provide 81 mg dose-specific statements or quantify “measurable” bleeding risk.
High-dose aspirin (325 mg or higher) increases bleeding risk further when paired with oral anticoagulants.
No dose-threshold (325 mg) relationship is provided in the provided excerpts.
Some clinicians drop aspirin entirely once a patient is stable on a direct oral anticoagulant for atrial fibrillation or venous thromboembolism.
The label excerpts do not discuss clinical practice patterns for stopping aspirin in atrial fibrillation/VTE when on direct oral anticoagulants.
In certain post-stent settings, clopidogrel or ticagrelor may replace aspirin.
The provided label excerpts do not address post-stent antiplatelet substitution with clopidogrel/ticagrelor.
Comparative trials suggest that replacing aspirin with clopidogrel or ticagrelor may produce lower bleeding rates.
No comparative trials or statements about replacing aspirin with clopidogrel/ticagrelor appear in the provided label excerpts.
Bright red or black stools are a symptom that should prompt emergency evaluation in this context.
Label excerpt mentions gross GI bleeding as a sign/alert, but does not provide triage/emergency-evaluation instructions or specify stool color.
Vomiting blood is a symptom that should prompt emergency evaluation in this context.
Label excerpt references gross GI bleeding/hematemesis in postmarketing list, but does not provide emergency triage instructions.
Severe unexplained bruising is a symptom that should prompt emergency evaluation in this context.
No such symptom-to-emergency triage mapping is included in the provided excerpts.
Dizziness on standing is a symptom that should prompt emergency evaluation in this context.
Label includes hypotension as a warning and vasodilation effects, but no instruction to “prompt emergency evaluation” for orthostatic dizziness.
Sudden severe headache is a symptom that should prompt emergency evaluation in this context.
No such symptom triage guidance is present in the provided excerpts.
Prolonged bleeding from cuts or frequent nosebleeds should prompt contacting a doctor rather than waiting in this context.
Label does not include this specific patient action guidance.
Contradictions
Important Omissions
The label’s specific indication for aspirin/dipyridamole (reducing risk of stroke in patients with prior transient ischemia of the brain or completed ischemic stroke due to thrombosis) is not addressed by the claims, which instead focus on “blood thinners” broadly.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the label does support increased bleeding risk with concomitant anticoagulants/antiplatelet agents, many additional claims provide unsourced quantitative rates, specific drug (DOAC) clearance times, COX-1/thromboxane mechanisms, and symptom triage instructions that are not supported by the provided prescribing information. These elements could mislead risk interpretation or patient decision-making relative to the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts (quantitative bleeding rates, DOAC clearance times, mechanism details, and emergency triage instructions), and the focus does not align with the label’s indication for aspirin/dipyridamole.
Suggested Improvement
Limit statements to those explicitly supported in the label excerpts (e.g., increased bleeding risk and general risk factors with anticoagulants/antiplatelets; mention intracranial/GI bleeding as described), and remove or qualify unsourced quantitative estimates, drug-specific PK (rivaroxaban/apixaban), mechanistic statements not present in the excerpts, and symptom-emergency action guidance.